{"eventGroups":[{"description":"This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to \\> 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day","id":"EG000","otherNumAffected":3,"otherNumAtRisk":59,"seriousNumAffected":5,"seriousNumAtRisk":59,"title":"BGG492"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":59}],"term":"Renal Cyst"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":59}],"term":"Adrenal Adenoma"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}],"term":"Angiomyolipoma"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 18.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}],"term":"Ovarian cyst"}]}